

In re Application of: Gary KLINEFELTER
 Serial No.: 09/752,514
 Filed: January 3, 2001
 For: METHOD FOR EVALUATING...



Art Unit: 1644
 Confirmation No.: 9981
 Examiner: P.J. NOLAN
 Washington, D.C.
 Atty.'s Docket: KLINEFELTER1C
 Date: October 11, 2002

7644
RECEIVED

OCT 16 2002

TECH CENTER 1600/290

THE COMMISSIONER OF PATENTS AND TRADEMARKS
 Washington, D.C. 20231

Sir:

Transmitted herewith is an [XX] Amendment [] _____ in the above-identified application.
 [] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
 [] A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
 [XX] No additional fee is required.

The fee has been calculated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)		Small Entity		Other Than a Small Entity	
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra		Rate	Additional Fee		Rate Additional Fee
Total	2	Minus	20	0		x 9	\$	x18	\$
Indep.	1	Minus	6	0		x42	\$	x84	\$
First Presentation of Multiple Dependent Claim						140	\$	+280	\$
* TOTAL ADDITIONAL CLAIMS FEE							\$	Total	\$

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col.1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required applicant requests that this be considered a petition therefor.

[] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity		Other Than Small Entity	
Response Filed Within		Response Filed Within	
[] First	- \$ 55.00	[] First	- \$ 110.00
[] Second	- \$200.00	[] Second	- \$ 400.00
[] Third	- \$460.00	[] Third	- \$ 920.00
[] Fourth	- \$720.00	[] Fourth	- \$1440.00

[] Less fees (\$) already paid for months extension of time on .

[] Please charge my Deposit Account No. 02-4035 in the amount of \$. A duplicate copy of this sheet is attached.

[] A check in the amount of \$ is attached (check no.).

[] Credit Card Payment Form, PTO-2038, authorizing payment in the amount of \$ is attached.


[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR Section 1.16 and all patent processing fees under 37 CFR Section 1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR Section 1.18.

BROWDY AND NEIMARK
 Attorneys for Applicant(s)

Facsimile: (202) 737-3528
 Telephone: (202) 628-5197

By:
 David M. Kornbau
 Registration No. 25,884

12/C
9nd
10/18/02



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: KLINEFELTER 1C

In re Application of:)	Art Unit: 1644
)	
Gary KLINEFELTER)	Examiner: P.J. NOLAN
)	
Serial No.: 09/752,514)	Confirmation No. 9981
)	
Filed: January 3, 2001)	Washington D.C.
)	
For: METHOD FOR EVALUATING)	October 11, 2002
AND AFFECTING MALE)	
FERTILITY)	

RECEIVED
OCT 16 2002
TECH CENTER 1600/2900

AMENDMENT

Honorable Commissioner for Patents
Washington, D.C. 20231

In response to the Office Action of
July 12, 2002, please enter the following amendment:

IN THE SPECIFICATION

Page 1, please amend paragraph [0001.] as follows:

C1 [0001.] The present invention relates to a sperm protein which can be used for evaluating, inhibiting, and/or enhancing male fertility, as well as antibodies to the sperm protein. The present application is a continuation in part of application Serial No. 09/123,492, filed July 28, 1998, now U.S. Patent No. 6,197,940 and PCTUS9701725 filed January 29, 1998, which is a continuation in part of application Serial No. 08/592,677, filed January 29, 1996 and now abandoned, both of which are hereby incorporated by reference in the entirety. The present application is based on and claims